...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Sparing the parotid glands and surgically transferred submandibular gland with helical tomotherapy in post-operative radiation of head and neck cancer: A planning study.
【24h】

Sparing the parotid glands and surgically transferred submandibular gland with helical tomotherapy in post-operative radiation of head and neck cancer: A planning study.

机译:头颈部癌术后放疗中保留腮腺和手术转移的下颌下腺并进行螺旋断层扫描:一项计划研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: To evaluate the feasibility of sparing the parotid glands and surgically transferred submandibular gland (SMG) by intensity modulated radiotherapy (IMRT) in post-operative cases of head and neck cancer (HNC). MATERIALS AND METHODS: Ten patients (larynx-2, base of tongue-4, tonsil-3, and unknown primary-1; pathologic stages III-IV) who underwent SMG transfers on the side of N0 neck along with definitive surgery were selected for this study. IMRT planning was done retrospectively using helical tomotherapy approach. Planning objective was to deliver 60Gy to PTV1 and 54Gy to PTV2 while maintaining the mean dose to the total parotid volume (TPV) and SMG less than 26Gy. RESULTS: The mean dose (+/-SD) to the TPV and SMG were 25+/-0.6Gy and 23+/-1.9Gy, respectively. The D(95) for PTV1 and PTV2 were 59.9+/-0.1Gy and 54.9+/-0.3Gy, respectively, satisfying our planning goal for PTV coverage. The D(99) for PTV1 and PTV2 were 58.2+/-0.7Gy and 49.5+/-2.2Gy, respectively, showing that sparing the salivary glands did not result in underdosing of the PTVs. CONCLUSIONS: By combining the gland transfer and IMRT, the mean dose to TPV and transferred SMG could be reduced to less than 26Gy in post-operative patients of HNC.
机译:背景与目的:评价通过调强放疗(IMRT)保留腮腺和手术转移的颌下腺(SMG)在头颈癌(HNC)术后病例中的可行性。材料与方法:选择十例患者(喉2,舌根4,扁桃体3和未知的原发性1;病理分期III-IV),在N0颈侧进行SMG转移并进行明确的手术。这项研究。 IMRT计划是使用螺旋断层扫描方法回顾性完成的。计划目标是将60Gy交付给PTV1,将54Gy交付给PTV2,同时保持腮腺总体积(TPV)和SMG的平均剂量小于26Gy。结果:TPV和SMG的平均剂量(+/- SD)分别为25 +/- 0.6Gy和23 +/- 1.9Gy。 PTV1和PTV2的D(95)分别为59.9 +/- 0.1Gy和54.9 +/- 0.3Gy,满足了我们对PTV覆盖范围的规划目标。 PTV1和PTV2的D(99)分别为58.2 +/- 0.7Gy和49.5 +/- 2.2Gy,表明保留唾液腺不会导致PTV剂量不足。结论:通过结合腺体转移和IMRT,HNC术后患者的TPV和转移SMG的平均剂量可降低至小于26Gy。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号